Trial Profile
Pilot / Phase II Randomised, Double Blind, Placebo Controlled Multicenter Study With Biomarker Evaluation of Neoadjuvant Exemestane in Combination With Sunitinib in Post-menopausal Women With Hormone- Sensitive, Her-2 Negative Primary Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Exemestane
- Indications Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Feb 2012 Status changed from recruiting to discontinued as reported by a European Clinical Trials database update.
- 13 Jul 2009 New trial record